如果大家喜欢这个视频别忘了点个赞并订阅频道哦!
点击这里订阅:https://bit.ly/2XZ8lKo
视频里穿的衣服：https://driotopia.com/
我的Ins: http://bit.ly/2HrYRgo
我的Bilibili: http://bit.ly/2HwYCRl
我的微博:http://bit.ly/2HvdqQj
BiliBili: 帅soserious
微博：帅soserious
抖音: 帅soserious
商务合作请加微信:to_s1ssy (请备注)
—————————————————————————————————————
大家周围有用减肥药的朋友吗？
#减肥 #减脂 #减肥药 #ozempic
———————————————————————
参考资料：
Aronne, Louis J., et al. “Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA, vol. 331, no. 1, 11 Dec. 2023, jamanetwork.com/journals/jama/fullarticle/2812936, https://doi.org/10.1001/jama.2023.24945.
borealisdev.net, and Dr Martin Juneau FRCP M. D. “Ozempic® (Semaglutide) and MounjaroTM (Tirzepatide), a Major Breakthrough for the Treatment of Obesity.” Observatoire de La Prévention de l’Institut de Cardiologie de Montréal, 2 Mar. 2023, observatoireprevention.org/en/2023/03/02/ozempic-semaglutide-and-mounjaro-tirzepatide-a-major-breakthrough-for-the-treatment-of-obesity/.
Bray, George A., and Jonathan Q. Purnell. “An Historical Review of Steps and Missteps in the Discovery of Anti-Obesity Drugs.” PubMed, MDText.com, Inc., 2000, www.ncbi.nlm.nih.gov/books/NBK581942/.
FDA. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” U.S. Food and Drug Administration, 2024, www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss.Grauslund, Jakob, et al. “Once-Weekly Semaglutide Doubles the Five-Year Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in a Danish Cohort of 424,152 Persons with Type 2 Diabetes.” International Journal of Retina and Vitreous, vol. 10, no. 1, 2024, p. 97, pubmed.ncbi.nlm.nih.gov/39696569/, https://doi.org/10.1186/s40942-024-00620-x.
Grundlingh, Johann, et al. “2,4-Dinitrophenol (DNP): A Weight Loss Agent with Significant Acute Toxicity and Risk of Death.” Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology, vol. 7, no. 3, 2011, pp. 205–12, www.ncbi.nlm.nih.gov/pubmed/21739343, https://doi.org/10.1007/s13181-011-0162-6.
Hayes, Hattie. “European Medicines Agency Will Assess Semaglutide for Link to NAION.” Ophthalmology Times, 20 Dec. 2024, europe.ophthalmologytimes.com/view/european-medicines-agency-will-assess-semaglutide-for-link-to-naion-ozempic-rare-eye-disease-glp-1-health-effects-vision. Accessed 25 Jan. 2025.